Maturation inhibitors as new antiretroviral agents.
John
J
Richards
Scott
S
McCallister
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006678:HIV / Q000502:physiology*; D016655:HIV Core Protein p24 / Q000037:antagonists & inhibitors; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D013386:Succinates / Q000494:pharmacology / Q000627:therapeutic use*; D014315:Triterpenes / Q000494:pharmacology / Q000627:therapeutic use*; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D016655:HIV Core Protein p24; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes